Categories
Change Password!
Reset Password!
Short-term nimesulide use demonstrates good tolera...
Taking NSAIDs after 60? Study warns of increased G...
A large hospital-based study from Beijing has identified significant risk factors associated with nonsteroidal anti-inflammatory drug (NSAID)-ind...
Low-dose aspirin raises gastric and duodenal ulcer...
A large population-based analysis of over 220,000 volunteers has revealed that low-dose aspirin initiation is connected with increased risk of ga...
Rabeprazole emerges as preferred PPI for GERD pati...
Tackling gastroesophageal reflux disease (GERD) in patients with multiple comorbidities and concurrent medications remains a clinical challenge,...
Tegoprazan emerges as fast-acting alternative to P...
A large study has positioned tegoprazan, a potassium-competitive acid blocker (PCAB), as a next-generation therapy for gastroesophageal reflux di...
Global PPI use hits 25%: Study flags rising long-t...
A large-scale systematic review assessing global trends in proton pump inhibitor (PPI) use has revealed that these acid-suppressing drugs are use...
Tradipitant
Tradipitant is a centrally acting antiemetic approved by the Food and Drug Administration (FDA) on 30 December 2025 for the prevention of motion...
High-dose vs. conventional therapy for H. pylori e...
Optimizing Helicobacter pylori (H. pylori) eradication therapy is fundamental in the era of rising antibiotic resistance.
Diagnosis and Management of GERD: Updates from Lyo...
Gastroesophageal reflux disease (GERD) is one of the most common gastrointestinal ailments globally, impacting approximately 1.03 billion individ...
Updated clinical guidance highlights optimal treat...
Helicobacter pylori (H. pylori) infection remains one of the most common chronic bacterial infections worldwide and is a major contributor to dys...
